Zenith Alpha腹主动脉支架移植物腔内动脉瘤修复的早期与中期结果:多中心回顾性托斯卡纳注册研究
该多中心回顾性注册研究纳入2016年1月至2021年11月7个中心202例择期EVAR患者,评估Zenith Alpha腹主动脉支架的早期与5年结果。30天技术与临床成功率分别为97.5%和99.5%,5年生存率73.6%,肢体移植物闭塞仍需关注,肢体构型未影响结局。
要点
- 30天技术与临床成功率分别为97.5%和99.5%,中位随访25.5个月。
- 估计5年无I/III型内漏、无手术转换、无移植物感染分别为88.6%、95.8%、97.7%。
- 5年无肢体移植物闭塞93.6%,ZSLE与ZISL构型间无显著差异(p=0.342)。
核心结论
- Zenith Alpha腹主动脉支架用于择期EVAR可获得满意的早期和5年结果,并发症率低;肢体移植物闭塞仍是问题,肢体构型未影响结局。
研究设计与样本
- 多中心回顾性注册研究,2016年1月至2021年11月7个中心共202例AAA患者行择期EVAR并植入Zenith Alpha腹主动脉支架。
- 评估30天技术成功与临床成功,采用Kaplan-Meier生命周期法分析估计5年结局。
- 比较不同肢体构型(Zenith Spiral Z AAA髂支,编码ZISL vs ZSLE)的肢体移植物闭塞。
主要发现
- 30天技术成功率为97.5%,临床成功率为99.5%。
- 中位随访25.5个月(四分位距12-43.25),5年生存率为73.6%。
- 估计5年无I/III型内漏为88.6%(95%CI 83.4%-93.1%),无手术转换为95.8%(95%CI 92.7%-97.1%)。
- 估计5年无肢体移植物闭塞为93.6%(95%CI 90.2%-96.8%),无任何器械相关再干预为87%(95%CI 83.3%-91.6%),无移植物感染为97.7%(95%CI 95.1%-98.9%)。
- 5年无肢体移植物闭塞ZSLE组93.4%(95%CI 89.8%-95.5%)vs ZISL组94.3%(95%CI 90.1%-95.9%),p=0.342,log-rank 0.903,无显著差异。
关键数值与推荐
- 30天技术成功97.5%,临床成功99.5%。
- 5年无I/III型内漏88.6%(95%CI 83.4%-93.1%),无手术转换95.8%(95%CI 92.7%-97.1%)。
- 5年无肢体移植物闭塞93.6%(95%CI 90.2%-96.8%),无器械相关再干预87%(95%CI 83.3%-91.6%),无移植物感染97.7%(95%CI 95.1%-98.9%)。
- ZSLE组5年无肢体移植物闭塞93.4%(95%CI 89.8%-95.5%)vs ZISL组94.3%(95%CI 90.1%-95.9%),p=0.342。
临床怎么用
- 作者认为,应采用包括髂动脉支架置入的标准化方案以降低肢体移植物闭塞。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Zenith Alpha Abdominal (Cook Medical, Bloomington, IN, USA) is one of the new-generation low-profile stent-grafts with demonstrated satisfactory early and midterm clinical outcomes for endovascular treatment of abdominal aortic aneurysms (AAAs). The aim was to evaluate early and midterm results of this device in the framework of a multicenter regional retrospective registry, with the analysis of morphological factors affecting outcomes, including different limb configurations. MATERIALS AND METHODS: Between January 2016 and November 2021, 202 patients with AAA underwent elective endovascular aneurysm repair (EVAR) with implantation of a Zenith Alpha Abdominal in 7 centers. Early (30 day) outcomes in terms of technical and clinical success were assessed. Estimated 5 year outcomes were evaluated in terms of survival, freedom from type I/III endoleak, freedom from surgical conversion, freedom from limb graft occlusion, freedom from any device-related reintervention, and graft infection evaluation by life-table analysis (Kaplan-Meier test). A comparative analysis between different limb configurations (Zenith Spiral Z AAA iliac legs, codes ZISL vs ZSLE) was performed in terms of limb graft occlusion. RESULTS: The 30 day technical and clinical success rates were 97.5% and 99.5%, respectively. Median follow-up period was 25.5 months (interquartile range [IQR]: 12-43.25). The 5 year survival rate was 73.6%. The estimated 5 year outcomes in terms of freedom from type I/III endoleak, freedom from surgical conversion, freedom from limb graft occlusion, freedom from any device-related reintervention, and freedom from graft infection were 88.6% (95% CI [confidence interval]: 83.4%-93.1%), 95.8% (95% CI: 92.7%-97.1%), 93.6% (95% CI: 90.2%-96.8%), 87% (95% CI: 83.3%-91.6%), and 97.7% (95% CI: 95.1%-98.9%), respectively. About limb configuration, no differences were found in terms of 5 year freedom from limb graft occlusion (ZSLE 93.4% [95% CI: 89.8%-95.5%] vs ZISL 94.3% [95% CI: 90.1%-95.9%], p=0.342; log-rank 0.903). CONCLUSION: Zenith Alpha Abdominal in elective EVAR offered satisfactory early and 5 year outcomes with low complication rates. Limb graft occlusion continued to be an issue. Limb configuration did not affect outcomes.Clinical ImpactThe authors describe satisfactory early and 5 year outcomes of Zenith Alpha Abdominal in elective endovascular aortic repair in the framework of a multicenter regional retrospective registry. At 5 years freedom from type I endoleak was 88.6%, and rate of endograft infections and conversions to open repair were very low. in the present study. Hot topic about about Zenith stent-graft still remains the limb graft occlusion with a 30-day overall rate of 2%, and estimated 5-year freedom from limb graft occlusion of 93.6%. Limb graft configuration did not affect limb graft occlusion rate. A standardized protocol including iliac stenting should be adopted to reduce kimb graft occlusion.
引用
- Troisi N, Pulli R, Donato G, et al. Early and Midterm Outcomes of Endovascular Aneurysm Repair With Zenith Alpha Abdominal Stent-Graft: Results From a Multicenter Retrospective Tuscany Registry. J Endovasc Ther. 2023. PMID: 37646124. doi:10.1177/15266028231197151
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。